甲胺和肝脏:释放全部治疗潜力
Federica Perazza1, Laura Leoni1, Santo Colosimo2
1Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40138 Bologna, Italy.
Metabolites
|April 26, 2024
概括
糖尿病药物梅特福明对肝脏健康有很大的前景. 它可能有助于预防肝癌,改善肝硬化,胰岛素耐药性和脂质失调等疾病.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
背景情况:
- 甲胺是2型糖尿病的第一线治疗方法.
- 新兴研究表明,甲福明的治疗潜力延伸到各种器官系统,特别是肝脏.
- 肝脏疾病通常与代谢功能障碍,胰岛素耐药性和脂质失调症有关.
研究的目的:
- 探索甲胺在肝脏疾病中的多方面的治疗益处.
- 调查甲福明在代谢功能障碍相关的脂肪性肝病 (MASLD) 和代谢功能障碍相关的脂肪性肝炎 (MASH) 中的作用.
- 评估甲福明对肝硬化,肝细胞癌 (HCC) 预防,胰岛素耐药性和脂质失调症的影响.
主要方法:
- 审查最近的科学文献和临床研究对甲胺对肝脏健康的影响.
- 对甲福明对代谢功能障碍,肝纤维化和瘤发展的影响数据的分析.
- 评估甲福明对胰岛素敏感性和脂质配置文件等关键代谢参数的影响.
主要成果:
- 甲福明对肝硬化有积极影响,具有抗瘤特性,有可能预防肝细胞癌.
- 虽然其在MASLD和MASH中的作用正在调查中,但甲福明可以改善胰岛素抵抗和胆固醇失调症,这在肝脏疾病患者中很常见.
- 临床前和临床数据表明,除了抗糖尿病作用之外,肝脏疾病有显著的益处.
结论:
- 甲胺对各种肝病,包括肝硬化和HCC预防具有有前途的治疗潜力.
- 该药物改善了相关的代谢并发症,如胰岛素耐药性和脂质失调症,这表明了更广泛的临床应用.
- 需要进一步的研究,以充分阐明甲胺在治疗各种肝脏疾病中的安全性和有效性.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Diabetes: Management and Pharmacotherapy
268
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
268


